探寻GPRC5A基因在乳腺癌中的角色：综述与展望
Exploring the Role of GPRC5A Gene in Breast Cancer: Review and Prospects
DOI: 10.12677/acm.2024.1461933, PDF,   
作者: 孙佳伟：内蒙古医科大学第一临床医学院，内蒙古 呼和浩特；马金柱*：内蒙古医科大学附属医院甲乳外科，内蒙古 呼和浩特
关键词: GPRC5A；GPCR家族；乳腺恶性肿瘤；靶向治疗；GPRC5A； GPCR Family； Breast Malignancies； Targeted Therapy
摘要: 据世界卫生组织国际癌症研究机构(IARC)发布的2022年全球最新癌症负担数据显示：2022年，全球女性新发癌症966万例，231万名妇女被诊断患有乳腺癌，67万人死亡，其中，中国女性新发癌症病例数229万，36万名妇女被诊断患有乳腺癌，8万人死亡。乳腺癌的病因十分复杂，到目前为止仍不明确，影响因素包括遗传、生活方式、环境等，是多个基因多个阶段多个通路之间协同作用的结果。最近研究发现G蛋白偶联受体家族C组5成员A (GPRC5A)在乳腺肿瘤的进展中有重要作用，但目前我国相关报道较少，该篇综述讲述了GPRC5A在乳腺癌发生发展中的一些作用，及其在乳腺恶性肿瘤中的治疗作用。
Abstract: According to the World Health Organization International Agency for Cancer Research (IARC) released in 2022, the latest cancer burden data show that in 2022, there were 9.66 million new cancer cases among women globally, with 2.31 million women diagnosed with breast cancer and 670,000 deaths. Among them, Chinese women accounted for 2.29 million new cancer cases, 360,000 women were diagnosed with breast cancer, 80,000 people died. The etiology of breast cancer is very complex and still unclear so far. The influencing factors include genetics, lifestyle, environment, etc., which are the result of the synergistic interaction between multiple genes, multiple stages and multiple pathways. Recently, it was found that A (GPRC5A), a member of group C 5 of G protein-coupled receptor family, has an important role in the progression of breast tumors, but there are few relevant reports in China. This review details the role of GPRC5A in the occurrence and development of breast cancer, and provides scientific basis for the study of breast cancer etiology in China.
文章引用：孙佳伟, 马金柱. 探寻GPRC5A基因在乳腺癌中的角色：综述与展望[J]. 临床医学进展, 2024, 14(6): 1448-1453. https://doi.org/10.12677/acm.2024.1461933

参考文献

[1] Zheng, R.S., Chen, R., Han, B.F., Wang, S.M., Li, L., Sun, K.X., Zeng, H.M., Wei, W.W. and He, J. (2024) [Cancer Incidence and Mortality in China, 2022]. Chinese Journal of Oncology, 46, 221-231.
[2] 刘宗超, 李哲轩, 张阳, 周彤, 张婧莹, 游伟程, 潘凯枫, 李文庆. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
[3] 张雅聪, 吕章艳, 宋方方, 等. 全球及我国乳腺癌发病和死亡变化趋势[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 14-20.
[4] 专家提醒: 1期乳腺癌5年生存率超过95%[J]. 中国社区医师(医学专业半月刊), 2008(21): 16.
[5] 付饶. 超微血管显像在乳腺癌早期诊断、病情判断及疗效评估中的价值[J]. 临床医学研究与实践, 2024, 9(9): 109-112.
[6] 黎立喜, 温霆宇, 管秀雯, 等. 早发性乳腺癌的遗传易感基因及临床特征[J]. 国际肿瘤学杂志, 2022, 49(4): 206-209.
[7] 程学远, 高雪原, 陈洁清, 等. 北海地区遗传性乳腺癌和健康遗传高危人群BRCA1和BRCA2基因突变研究[J].吉林医学, 2024, 45(3): 528-531.
[8] 王婕, 蒋倩. p53、Ki67、CK5/6、AR在三阴性乳腺癌组织中表达情况及意义[J]. 黑龙江医药, 2024, 37(1): 206-208.
[9] 方新颜, 顾颖慧, 施艳琳. 乳腺癌组织中FMNL3、PTEN的表达及其与临床病理特征的关系[J]. 中外医学研究, 2023, 21(9): 118-122.
[10] 周阳, 吕珊珊, 马晓周, 等. G蛋白偶联受体C家族5A的研究进展[J]. 现代肿瘤医学, 2017, 25(9): 1499-1502.
[11] Jiang, X., Xu, X., Wu, M., Guan, Z., Su, X., Chen, S., et al. (2018) GPRC5A: An Emerging Biomarker in Human Cancer. BioMed Research International, 2018, Article ID: 1823726. [Google Scholar] [CrossRef] [PubMed]
[12] Dai, L., Jin, X. and Liu, Z. (2021) Prognostic and Clinicopathological Significance of GPRC5A in Various Cancers: A Systematic Review and Meta-Analysis. PLOS ONE, 16, e0249040. [Google Scholar] [CrossRef] [PubMed]
[13] Iglesias González, P.A., Valdivieso, Á.G. and Santa-Coloma, T.A. (2023) The G Protein-Coupled Receptor Gprc5a—A Phorbol Ester and Retinoic Acid-Induced Orphan Receptor with Roles in Cancer, Inflammation, and Immunity. Biochemistry and Cell Biology, 101, 465-480. [Google Scholar] [CrossRef] [PubMed]
[14] Fang, W., Yu, X., Deng, J., Yu, B., Xiong, J. and Ma, M. (2023) Upregulated GPRC5A Disrupting the Hippo Pathway Promotes the Proliferation and Migration of Pancreatic Cancer Cells via the cAMP-CREB Axis. Discover Oncology, 14, Article No. 17. [Google Scholar] [CrossRef] [PubMed]
[15] 元建华, 张曙波, 李建旺, 等. GPRC5A、SOCS3和STAT3在结直肠癌组织中的表达及相关性分析[J]. 中国癌症防治杂志, 2019, 11(6): 518-522.
[16] Yang, L., Ma, T. and Zhang, J. (2016) GPRC5A Exerts Its Tumor-Suppressive Effects in Breast Cancer Cells by Inhibiting EGFR and Its Downstream Pathway. Oncology Reports, 36, 2983-2990. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, T., Jing, B., Xu, D., Liao, Y., Song, H., Sun, B., et al. (2020) PTGES/PGE2 Signaling Links Immunosuppression and Lung Metastasis in Gprc5a-Knockout Mouse Model. Oncogene, 39, 3179-3194. [Google Scholar] [CrossRef] [PubMed]
[18] Guo, W., Hu, M., Wu, J., Zhou, A., Liao, Y., Song, H., et al. (2019) Gprc5a Depletion Enhances the Risk of Smoking-Induced Lung Tumorigenesis and Mortality. Biomedicine & Pharmacotherapy, 114, Article ID: 108791. [Google Scholar] [CrossRef] [PubMed]
[19] 李星枝, 王舰梅, 肖秀丽, 等. GATA-3和EGFR在乳腺癌中表达的相关性及其与分子亚型、临床病理资料的关系[J]. 川北医学院学报, 2021, 36(4): 414-418.
[20] 黄华奇, 闻剑波, 江明君, 等. GPRC5A抑制肺癌细胞A549增殖和迁移及与EGFR的相关性研究[J]. 浙江医学, 2018, 40(24): 2667-2670.
[21] Liu, Y., Bai, Z., Chai, D., Gao, Y., Li, T., Ma, Y., et al. (2022) DNA Methyltransferase 1 Inhibits MicroRNA-497 and Elevates GPRC5A Expression to Promote Chemotherapy Resistance and Metastasis in Breast Cancer. Cancer Cell International, 22, Article No. 112. [Google Scholar] [CrossRef] [PubMed]
[22] Liu, H., Song, Y., Qiu, H., Liu, Y., Luo, K., Yi, Y., et al. (2019) Downregulation of FOXO3a by DNMT1 Promotes Breast Cancer Stem Cell Properties and Tumorigenesis. Cell Death & Differentiation, 27, 966-983. [Google Scholar] [CrossRef] [PubMed]
[23] Tao, S., Li, H., Ma, X., Lian, B., He, J., Gao, Y., et al. (2020) Methylation-mediated Silencing of MicroRNA-497 Promotes Breast Cancer Progression through Up-Regulation of Mucin1. Frontiers in Oncology, 10, Article 552099. [Google Scholar] [CrossRef] [PubMed]
[24] Yang, L., Zhao, S., Zhu, T. and Zhang, J. (2021) GPRC5A Is a Negative Regulator of the Pro-Survival PI3K/Akt Signaling Pathway in Triple-Negative Breast Cancer. Frontiers in Oncology, 10, Article 624493. [Google Scholar] [CrossRef] [PubMed]
[25] 王雅娟, 王媛, 任新瑜. 三阴性乳腺癌患者CD117、DOG1表达水平与临床病理特征及预后的相关性[J]. 协和医学杂志, 2024, 15(3): 616-623.
[26] 研究揭示SF3A2可作为三阴性乳腺癌的潜在治疗新靶点[J]. 海南医学, 2024, 35(8): 1217-1218.
[27] Verret, B., Cortes, J., Bachelot, T., Andre, F. and Arnedos, M. (2019) Efficacy of PI3K Inhibitors in Advanced Breast Cancer. Annals of Oncology, 30, x12-x20. [Google Scholar] [CrossRef] [PubMed]
[28] 沈云燕, 邱琦. 达沙替尼基于PI3K/AKT信号通路调节乳腺癌细胞生物学行为[J]. 现代肿瘤医学, 2024, 32(7): 1194-1199.
[29] 张智颖, 孙军峰, 师乾凯, 等. Rho GTP酶和肌动蛋白细胞骨架对新城疫病毒在细胞间传播的影响[J/OL]. 中国兽医科学: 1-9.
https://kns.cnki.net/kcms2/article/abstract?v=m22VhQxdXyc1AjK-C9M8AP6_Gxi5mCIK_UAR8E7hdSXwiwCg3ttah8HMsqshSyy5D432HzCuZB4sSboJUdaIE64S0Ojs9FrmmFc9MmawVX5Xt448H1BoD3NUJBo7F7fVV4MQL0HLgEo=&uniplatform=NZKPT&flag=copy, 2024-05-06.
[30] Richter, L., Oberländer, V. and Schmidt, G. (2020) RhoA/C Inhibits Proliferation by Inducing the Synthesis of GPRC5A. Scientific Reports, 10, Article No. 12532. [Google Scholar] [CrossRef] [PubMed]
[31] 关晓英. ARHGAP11A通过TPM1调控肌动蛋白微丝形成促进胃癌迁移和侵袭的机制研究[D]：[博士学位论文]. 兰州大学, 2024.
[32] Klaschik, K., Hauke, J., Neidhardt, G., Tränkle, C., Surowy, H.M., Heilmann‐Heimbach, S., et al. (2019) The GPRC5A Frameshift Variant c.183del Is Not Associated with Increased Breast Cancer Risk in BRCA1 Mutation Carriers. International Journal of Cancer, 144, 1761-1763. [Google Scholar] [CrossRef] [PubMed]
[33] 苟佳佳, 李靖柯, 李硕. G蛋白偶联受体及其靶向药物研究[J]. 中国药房, 2018, 29(19): 2728-2732.
[34] 杨文青, 王静, 王丽, 等. HER2阳性乳腺癌患者行帕妥珠单抗靶向治疗过程中应用预见性护理的效果[J]. 中国药物滥用防治杂志, 2024, 30(2): 358-361.

为你推荐